Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

345 ARTÍCULOS , VIENDO DEL 76 AL 90

Cholinesterase inhibitors in vascular cognitive impairment

Massoud F.

Can J Neurol Sci. 2013 Jul;40(4):446-7. doi: 10.1017/s0317167100014487.

γ-Secretase inhibitors and modulators

Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L.

Biochim Biophys Acta. 2013 Dec;1828(12):2898-907. doi: 10.1016/j.bbamem.2013.06.005. Epub 2013 Jun 17.

Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease

Ashby EL, Kehoe PG.

Expert Opin Investig Drugs. 2013 Oct;22(10):1229-42. doi: 10.1517/13543784.2013.812631. Epub 2013 Jun 26.

Is a potential Alzheimer's therapy already in use for other conditions? Can medications for hypertension, diabetes and acne help with the symptoms?

Corbett A, Ballard C.

Expert Opin Investig Drugs. 2013 Aug;22(8):941-3. doi: 10.1517/13543784.2013.815723. Epub 2013 Jul 1.

Mens sana in corpore sano revisited

Jeger RV.

Eur Heart J. 2013 Sep;34(33):2580-1. doi: 10.1093/eurheartj/eht244. Epub 2013 Jul 4.

The role of polyphenols in the modulation of sirtuins and other pathways involved in Alzheimer's disease

Jayasena T, Poljak A, Smythe G, Braidy N, Münch G, Sachdev P.

Ageing Res Rev. 2013 Sep;12(4):867-83. doi: 10.1016/j.arr.2013.06.003. Epub 2013 Jul 5.

Reversing heart failure by CRT: how long do the effects last?

Breithardt OA.

Eur Heart J. 2013 Sep;34(33):2582-4. doi: 10.1093/eurheartj/eht238. Epub 2013 Jul 4.

A paradigm shift for evaluating pharmacotherapy for Alzheimer's disease: the 10-patient screening protocol

Weinstein JD, Gonzalez ER, Egleton RD, Hunt DA.

Consult Pharm. 2013 Jul;28(7):443-54. doi: 10.4140/TCP.n.2013.443.

BACE1 as a therapeutic target in Alzheimer's disease: rationale and current status

Evin G, Hince C.

Drugs Aging. 2013 Oct;30(10):755-64. doi: 10.1007/s40266-013-0099-3.

Update on Alzheimer's disease therapeutics

Rafii MS.

Rev Recent Clin Trials. 2013 Jun;8(2):110-8. doi: 10.2174/15748871113089990045.

Novel γ-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012

Pettersson M, Stepan AF, Kauffman GW, Johnson DS.

Expert Opin Ther Pat. 2013 Oct;23(10):1349-66. doi: 10.1517/13543776.2013.821465. Epub 2013 Jul 23.

Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease

Yáñez M, Viña D.

Curr Top Med Chem. 2013;13(14):1692-706. doi: 10.2174/15680266113139990120.

Changes in Mini-Mental State Examination score in Alzheimer's disease patients after stopping habitual drinking

Toda A, Tagata Y, Nakada T, Komatsu M, Shibata N, Arai H.

Psychogeriatrics. 2013 Jun;13(2):94-8. doi: 10.1111/psyg.12008.

Neuroprotective properties of curcumin in Alzheimer's disease--merits and limitations

Chin D, Huebbe P, Pallauf K, Rimbach G.

Curr Med Chem. 2013;20(32):3955-85. doi: 10.2174/09298673113209990210.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias